D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games and P. Seubert, “Immunization with Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in PDAPP Mouse,” Nature, Vol. 400, No. 6740, 1999, pp. 173-177. doi:10.1038/22124

has been cited by the following article:

• TITLE: The Functions of the Amyloid Precursor Protein Gene and Its Derivative Peptides: III Pharmacological Studies

  AUTHORS: Peter K. Panegyres, Emily R. Atkins

  KEYWORDS: Amyloid Precursor Protein, APP, Genes, Dementia, Alzheimer’s Disease

  JOURNAL NAME: Neuroscience and Medicine, Vol.2 No.4, December 2, 2011

  ABSTRACT: Pharmacological studies reveal APP and Aβ have interactions with glutamate and calcium, cytokines, copper/zinc chelators, secretases and presenilins, nicotinic receptors, acetycholinesterase, neurotrophins, non-steroidal anti-inflame-matory drugs, monoclonal antibodies to Aβ, protease inhibitors, oestrogen, homocysteine, immediate early genes such as c-fos or c-jun and cholesterol. These functional and pharmacological observations highlight the need for greater understanding of APP and Aβ in brain function and have implications for clinical trials.